应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CXO 康休
退市 01-15 16:00:00 EST
65.60
+0.00
0.00%
最高
65.60
最低
65.60
成交量
0.00
今开
65.60
昨收
65.60
日振幅
0.00%
总市值
127.60亿
流通市值
126.27亿
总股本
1.95亿
成交额
0.00
换手率
0.00%
流通股本
1.92亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
港股异动 | CRO概念股延续反弹 下游需求端有待好转 国内CXO公司仍具备竞争优势
智通财经 · 04-29
港股异动 | CRO概念股延续反弹 下游需求端有待好转 国内CXO公司仍具备竞争优势
百亿基金经理如何看市场焦点?
华尔街见闻 · 04-23
百亿基金经理如何看市场焦点?
沪深三大板块IPO标准迎新:超40家在审项目面临考验
华尔街见闻 · 04-13
沪深三大板块IPO标准迎新:超40家在审项目面临考验
多家CXO公司去年营收增速放缓,行业回暖仍在路上
36氪 · 04-10
多家CXO公司去年营收增速放缓,行业回暖仍在路上
港股CXO迎集体降速时刻,下行周期何时结束?
智通财经 · 04-09
港股CXO迎集体降速时刻,下行周期何时结束?
港股收评:V型反弹!恒生科技指数跌0.29%,CXO、中海油服遭重挫
格隆汇 · 04-05
港股收评:V型反弹!恒生科技指数跌0.29%,CXO、中海油服遭重挫
CXO行业增速变奏,龙头公司传递产业冷暖
36氪 · 04-03
CXO行业增速变奏,龙头公司传递产业冷暖
港股午评:恒生科技指数跌1.77% 新能源汽车、CXO概念领跌
东方财富Choice... · 03-19
港股午评:恒生科技指数跌1.77% 新能源汽车、CXO概念领跌
【券商聚焦】招银国际料中国主要CXO公司最早在2024年下半年重新进入业绩加速通道
金吾财讯 · 03-15
【券商聚焦】招银国际料中国主要CXO公司最早在2024年下半年重新进入业绩加速通道
快讯:港股三大指数低开低走 科网股、CXO概念股、汽车股跌幅居前
新浪港股 · 03-15
快讯:港股三大指数低开低走 科网股、CXO概念股、汽车股跌幅居前
CXO寒冬了
虎嗅APP · 03-07
CXO寒冬了
快讯:港股三大指数探底回升 黄金、石油股走强 CXO概念股大跌
新浪港股 · 03-07
快讯:港股三大指数探底回升 黄金、石油股走强 CXO概念股大跌
5000亿资产重大突发 CXO板块大涨原因或找到
券商中国 · 03-04
5000亿资产重大突发 CXO板块大涨原因或找到
智通港股解盘 | CXO类暂停做空 巨头变革谋发展
智通财经网 · 02-05
智通港股解盘 | CXO类暂停做空 巨头变革谋发展
药明康德A股再跌停,CXO及基因检测概念两日内蒸发超千亿丨钛媒体焦点
钛媒体APP · 01-29
药明康德A股再跌停,CXO及基因检测概念两日内蒸发超千亿丨钛媒体焦点
海外提案引发“药明系”惊魂一跳,CXO噩梦又被唤醒
钛媒体网 · 01-27
海外提案引发“药明系”惊魂一跳,CXO噩梦又被唤醒
CXO不确定性仍在,医药女神”葛兰大幅减仓
钛媒体APP · 01-25
CXO不确定性仍在,医药女神”葛兰大幅减仓
【券商聚焦】交银国际削金斯瑞(01548)目标价3%至27.6港元 指当前CXO板块投资情绪仍未明显恢复
金吾资讯 · 01-25
【券商聚焦】交银国际削金斯瑞(01548)目标价3%至27.6港元 指当前CXO板块投资情绪仍未明显恢复
【券商聚焦】招银国际削药明生物(02269)目标价11.22% 指海外CXO同行对行业趋势仍持谨慎态度
金吾财讯 · 01-18
【券商聚焦】招银国际削药明生物(02269)目标价11.22% 指海外CXO同行对行业趋势仍持谨慎态度
港股午评:恒生科技指数跌3.87%,CXO、一体化压铸概念领跌,小鹏汽车跌近9%
界面 · 01-17
港股午评:恒生科技指数跌3.87%,CXO、一体化压铸概念领跌,小鹏汽车跌近9%
暂无数据
公司概况
公司名称:
康休
所属市场:
NYSE
上市日期:
--
主营业务:
Concho Resources Inc.成立于2006年2月22日,是一家于2006年2月在特拉华州注册成立的公司,是一家独立的石油和天然气公司,从事石油和天然气资产的收购、开发、勘探和生产。
发行价格:
--
{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","marketStatusCode":7,"change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"listingDate":1186113600000,"adjPreClose":65.6,"adrRate":0,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO/tweets","defaultTab":"tweets","newsList":[{"id":"2431702579","title":"港股异动 | CRO概念股延续反弹 下游需求端有待好转 国内CXO公司仍具备竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2431702579","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431702579?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:55","pubTimestamp":1714359352,"startTime":"0","endTime":"0","summary":"中信建投指出,目前医药领域一级投融资仍有待恢复,下游需求端有待好转。该行指出,国内CXO公司相比全球企业仍具备一定竞争优势,近年来在ADC、多肽药物快速发展下,相关CXO需求迅速增加,小核酸、CGT等细分领域也有望迎来快速发展。临床CRO领域匹配高端需求的公司有望获得更高份额。目前CXO板块整体估值处于低位,长期来看,我们仍旧看好CXO板块发展潜力及成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113909.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429918661","title":"百亿基金经理如何看市场焦点?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429918661","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2429918661?lang=zh_cn&edition=full","pubTime":"2024-04-23 07:59","pubTimestamp":1713830352,"startTime":"0","endTime":"0","summary":"易方达张坤认为,从长期国债和类债的股票资产表现来看,市场的风险偏好已经降低到了很低的水平,具体表现为在定价时给予静态的股息率水平很高的权重,对成长性特别是企业的长期成长性持怀疑的态度。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/d9693536-1637-455f-8a27-5115dd0aaed5.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/d9693536-1637-455f-8a27-5115dd0aaed5.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3713331","is_publish_highlight":false,"gpt_icon":0},{"id":"2427799046","title":"沪深三大板块IPO标准迎新:超40家在审项目面临考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2427799046","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2427799046?lang=zh_cn&edition=full","pubTime":"2024-04-13 10:43","pubTimestamp":1712976188,"startTime":"0","endTime":"0","summary":"业绩踩线难言乐观","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/content_default_8.jpg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/content_default_8.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712638","is_publish_highlight":false,"gpt_icon":0},{"id":"2426482818","title":"多家CXO公司去年营收增速放缓,行业回暖仍在路上","url":"https://stock-news.laohu8.com/highlight/detail?id=2426482818","media":"36氪","top":-1,"share":"https://www.laohu8.com/m/news/2426482818?lang=zh_cn&edition=full","pubTime":"2024-04-10 08:25","pubTimestamp":1712708720,"startTime":"0","endTime":"0","summary":"从公布的数据来看,多家CXO公司的营业收入增速相比以往出现下滑,且存在较为明显的分化。头豹研究院分析师谭志坚表示,CXO公司的业绩根基在于医药研发生产的持续投入。自2023年开始,行业投融资大环境降温,药企纷纷收缩研发管线,导致CXO企业整体订单数量下滑明显。对于行业是否回暖,每家企业的“体感温度”并不相同。有...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240410A015FR00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240410A015FR00","is_publish_highlight":false,"gpt_icon":0},{"id":"2426415834","title":"港股CXO迎集体降速时刻,下行周期何时结束?","url":"https://stock-news.laohu8.com/highlight/detail?id=2426415834","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426415834?lang=zh_cn&edition=full","pubTime":"2024-04-09 15:33","pubTimestamp":1712648021,"startTime":"0","endTime":"0","summary":"消息传出后,早已是“惊弓之鸟”的港股CXO板块集体下挫。CXO下行周期中的业绩分化虽然2023年国内CXO板块集体承压,但作为港股CXO板块的四大头部企业,康龙化成、昭衍新药、凯莱英、泰格医药在2023年的业绩表现却分化明显。而凯莱英当期营收为78.25亿元,同比下降23.70%;归母净利润为22.69亿元,同比下降31.28%。虽说全球CXO板块中长期发展趋势不会改变,但对公司来说,海外业务增长的同时,业务及收入结构或许难免会出现变化。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099917.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2425053485","title":"港股收评:V型反弹!恒生科技指数跌0.29%,CXO、中海油服遭重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2425053485","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2425053485?lang=zh_cn&edition=full","pubTime":"2024-04-05 16:51","pubTimestamp":1712307060,"startTime":"0","endTime":"0","summary":"朗廷-SS因有望私有化退市,暴涨41%","market":"us","thumbnail":"https://img3.gelonghui.com/442f4-225f5f62-62e8-4a54-8c80-004f29e3b51c.png","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/442f4-225f5f62-62e8-4a54-8c80-004f29e3b51c.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/716101","is_publish_highlight":false,"gpt_icon":0},{"id":"2424788356","title":"CXO行业增速变奏,龙头公司传递产业冷暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2424788356","media":"36氪","top":-1,"share":"https://www.laohu8.com/m/news/2424788356?lang=zh_cn&edition=full","pubTime":"2024-04-03 07:40","pubTimestamp":1712101235,"startTime":"0","endTime":"0","summary":"随着药企2023年度业绩报告的集中披露,医药外包服务行业(CXO)的基本面现状逐渐浮出水面。从业绩表现来看,CXO行业企业业绩一路高歌的势头逐渐式微,新药研发领域“避风港”似乎正在消失。但细究行业龙头公司年报不难发现,即使整个生物科技行业仍处周期低谷,且受到地缘政治等非理性因素困扰,CXO行业依然不乏亮点。长期...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240403A00P6W00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240403A00P6W00","is_publish_highlight":false,"gpt_icon":0},{"id":"2420267590","title":"港股午评:恒生科技指数跌1.77% 新能源汽车、CXO概念领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2420267590","media":"东方财富Choice...","top":-1,"share":"https://www.laohu8.com/m/news/2420267590?lang=zh_cn&edition=full","pubTime":"2024-03-19 12:06","pubTimestamp":1710821195,"startTime":"0","endTime":"0","summary":"【港股午评:恒生科技指数跌1.77% 新能源汽车、CXO概念领跌】港股早盘指数低位震荡,恒生指数跌1.11%,报收16550.9点;恒生科技指数跌1.77%,报收3530.44点。板块方面,猪肉股、百货业概念股领涨;新能源汽车概念股、CXO概念股领跌。热门个股方面,药明康德跌超6%,优必选涨超3%,理想汽车跌超9%,药明生物、小鹏汽车跌超4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1353,202403193016490454.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419916769","title":"【券商聚焦】招银国际料中国主要CXO公司最早在2024年下半年重新进入业绩加速通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2419916769","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2419916769?lang=zh_cn&edition=full","pubTime":"2024-03-15 13:57","pubTimestamp":1710482239,"startTime":"0","endTime":"0","summary":"该行预计,从融资改善到CXO业绩反弹,将经历一定的时间周期,而2024年下半年全球CXO行业或将迎来需求周期的向上拐点。中国CXO公司的这一轮业绩减速时间点相比海外同行滞后约2至4个季度,主要可能是由于新冠订单节奏的影响。考虑到业绩基数的影响以及中国融资复苏节奏或将慢于海外,该行预计中国主要CXO公司将最早在2024年下半年重新进入业绩加速通道。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1933397","is_publish_highlight":false,"gpt_icon":0},{"id":"2419700996","title":"快讯:港股三大指数低开低走 科网股、CXO概念股、汽车股跌幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2419700996","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2419700996?lang=zh_cn&edition=full","pubTime":"2024-03-15 11:01","pubTimestamp":1710471660,"startTime":"0","endTime":"0","summary":" 3月15日消息,今日港股三大指数低开低走,截至发稿,恒生指数跌2.03%,报16618.18点,恒生科技指数跌2.86%,国企指数跌2.31%。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-15/doc-inankiew6976492.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-15/doc-inankiew6976492.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417138767","title":"CXO寒冬了","url":"https://stock-news.laohu8.com/highlight/detail?id=2417138767","media":"虎嗅APP","top":-1,"share":"https://www.laohu8.com/m/news/2417138767?lang=zh_cn&edition=full","pubTime":"2024-03-07 21:44","pubTimestamp":1709819040,"startTime":"0","endTime":"0","summary":"不涉及“制裁”,CXO行业的业绩“寒冬”也难改变。不及市场预期的情况下,次日CXO板块全线走弱。即,若法案通过,国内CXO行业的未来发展不容乐观。#02不涉及“制裁”,CXO的业绩“寒冬”难改变由上述,CXO企业的业绩主要依赖于下游药企的新药研发订单外包。但实质上随着行业内卷,头部的CXO企业也在拓展小型和初创药企,且近几年小型和初创药企已经成为了业绩的主要来源之一。则,2024年度国内CXO企业的订单承接和交付情况大概率不会很好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2655991250&idx=3&sn=a5156e1edc454674bfeab4ab3b797604&chksm=675baaabc083e524877543761d2d560cbbecffb220d50f7fb8c672271629817367bdaab08db0&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2417036802","title":"快讯:港股三大指数探底回升 黄金、石油股走强 CXO概念股大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2417036802","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2417036802?lang=zh_cn&edition=full","pubTime":"2024-03-07 10:53","pubTimestamp":1709779980,"startTime":"0","endTime":"0","summary":" 3月7日消息,今日港股三大指数探底回升,截至发稿,恒生指数涨0.19%,报16469.57点,恒生科指涨0.23%,国企指数涨0.74%。股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-07/doc-inamnhkn7862869.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-03-07/doc-inamnhkn7862869.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2416568961","title":"5000亿资产重大突发 CXO板块大涨原因或找到","url":"https://stock-news.laohu8.com/highlight/detail?id=2416568961","media":"券商中国","top":-1,"share":"https://www.laohu8.com/m/news/2416568961?lang=zh_cn&edition=full","pubTime":"2024-03-04 11:03","pubTimestamp":1709521380,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 医药这个板块还是挺磨人的。这使得今天早盘,CXO板块整体大涨。在经历了连续两个交易日的反弹之后,A股早盘表现乏力,截至发稿,两市上涨个股不足2000只,市场似乎又回到了弱市格局。在此消息发布之后,中国的CXO板块出现暴跌行情。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/jsy/2024-03-04/doc-inamckxq5269688.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/jsy/2024-03-04/doc-inamckxq5269688.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2409310032","title":"智通港股解盘 | CXO类暂停做空 巨头变革谋发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2409310032","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2409310032?lang=zh_cn&edition=full","pubTime":"2024-02-05 18:59","pubTimestamp":1707130786,"startTime":"0","endTime":"0","summary":"港股能不能在这里扛住还不好说,因为也有跌幅较大的品种,而且下跌的品种占多数。说明多空依旧处于分歧当中,继续观察A股能否企稳。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20190129/20190129154339_50532.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20190129/20190129154339_50532.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1068653.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2407866102","title":"药明康德A股再跌停,CXO及基因检测概念两日内蒸发超千亿丨钛媒体焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2407866102","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2407866102?lang=zh_cn&edition=full","pubTime":"2024-01-29 21:27","pubTimestamp":1706534840,"startTime":"0","endTime":"0","summary":"图源自视觉中国“药明系”个股继续领跌板块,华大智造跌幅放大。1月29日,药明康德(603259.SH/02359.HK)A股低开低走,盘中跌停封死,收于59.36元。而药明康德港股跌幅更大,周一收跌10.60%。周一,机构净卖出前三的股票分别是药明康德、TCL中环、中华企业,净流出金额分别是9.84亿元、1.43亿元、3258万元,药明康德净卖出...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/ORutZNIfscBrVV7FklUE-qdWJqHEVzl3fIV5iddfSWqF4AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/ORutZNIfscBrVV7FklUE-qdWJqHEVzl3fIV5iddfSWqF4AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240129A08WE200","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240129A08WE200","is_publish_highlight":false,"gpt_icon":0},{"id":"2406754147","title":"海外提案引发“药明系”惊魂一跳,CXO噩梦又被唤醒","url":"https://stock-news.laohu8.com/highlight/detail?id=2406754147","media":"钛媒体网","top":-1,"share":"https://www.laohu8.com/m/news/2406754147?lang=zh_cn&edition=full","pubTime":"2024-01-27 12:07","pubTimestamp":1706328420,"startTime":"0","endTime":"0","summary":" ▎药明康德(维权)A股跌停,港股一度跌超32%;药明生物港股盘中最大跌幅26.83%;分拆自药明生物的药明合联同步跳水,收跌20.00%。 消息面上,业内流传美国拟出台《生物安全法案》,并直指华大基因及子公司华大智造、Complete Genomics,以及药明康德将受限制。 截至发稿,已有多家上市公司作出首轮回应。 药明康德也表示,将会发布公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/2024-01-27/doc-inaexwae3630358.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2024-01-27/doc-inaexwae3630358.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2406628900","title":"CXO不确定性仍在,医药女神”葛兰大幅减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2406628900","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2406628900?lang=zh_cn&edition=full","pubTime":"2024-01-25 09:57","pubTimestamp":1706147839,"startTime":"0","endTime":"0","summary":"来源于视觉中国近日,各大公募基金纷纷披露四季度报告,明星基金经理的调仓路径也随之公之于众,其中有“医药女神”之称的葛兰在管医药公募基金备受市场关注。根据中欧基金披露的旗下基金经理葛兰在管公募基金“中欧医疗健康混合基金”的2023年四季报,葛兰在四季度对创新药等进行了加仓,对CXO类股票一律减仓,包括药明康...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/Oy7LVWWTz9Fyixwl_ladW4st8LjdcYsBq5SzqF5ybYiRkAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Oy7LVWWTz9Fyixwl_ladW4st8LjdcYsBq5SzqF5ybYiRkAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240125A022K800","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240125A022K800","is_publish_highlight":false,"gpt_icon":0},{"id":"2406288148","title":"【券商聚焦】交银国际削金斯瑞(01548)目标价3%至27.6港元 指当前CXO板块投资情绪仍未明显恢复","url":"https://stock-news.laohu8.com/highlight/detail?id=2406288148","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2406288148?lang=zh_cn&edition=full","pubTime":"2024-01-25 09:10","pubTimestamp":1706145041,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发研报指,金斯瑞 子公司传奇生物的合作伙伴强生于今日盘前公布4Q23业绩,其中cilta-cel录得销售1.59亿美元的销售额,符合该行此前的预期。该行认为:1)当前港股CXO板块的投资情绪仍未明显恢复,相比传统生物大分子,GCT外包服务的订单增长前景和长期景气度能见度强,当前存在较大预期差;2)传奇生物当前111亿美元的估值和cilta-cel的适应症拓展、销售放量预期仍未完全反映在金斯瑞的股价中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012509111081e198be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012509111081e198be&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404378178","title":"【券商聚焦】招银国际削药明生物(02269)目标价11.22% 指海外CXO同行对行业趋势仍持谨慎态度","url":"https://stock-news.laohu8.com/highlight/detail?id=2404378178","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2404378178?lang=zh_cn&edition=full","pubTime":"2024-01-18 14:49","pubTimestamp":1705560545,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研报指,药明生物 更新近期业务进展,23年全年新增项目132个,基本维持疫情期间的水平,管理层预计2Q24开始业务将持续向好。另外,海外CXO同行对行业趋势仍持谨慎态度。该行维持“买入”评级,目标价由44.66港元下调11.22%至39.65港元。该行预计药明生物2023E/24E/25E收入增速为10.2%/14.5%/29.0%,经调整归母净利润增速为-6.0%/13.5%/27.8%,对应现阶段股价的FY24E市盈率分别为25/22/17倍。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/YWJkMTExMDAwMDkzNTUyODE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/YWJkMTExMDAwMDkzNTUyODE=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1930055","is_publish_highlight":false,"gpt_icon":0},{"id":"2404710348","title":"港股午评:恒生科技指数跌3.87%,CXO、一体化压铸概念领跌,小鹏汽车跌近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2404710348","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2404710348?lang=zh_cn&edition=full","pubTime":"2024-01-17 12:01","pubTimestamp":1705464070,"startTime":"0","endTime":"0","summary":"1月17日,港股半天下来,指数持续跳水,恒生指数跌2.81%,报收15419.68点;恒生科技指数跌3.87%,报收3197.25点。板块方面,虚拟现实概念股、殡葬股领涨;CXO概念股、一体化压铸概念股领跌。热门个股方面,小鹏汽车跌近9%,美团跌超5%,小米集团跌超4%,东方甄选跌超3%,腾讯控股跌近3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401171201107a3bd22d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401171201107a3bd22d&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日,是一家于2006年2月在特拉华州注册成立的公司,是一家独立的石油和天然气公司,从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}